Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Biotechnology company Destiny Pharma reported wider losses on higher costs in the first half of the year.
For the half-year ended 30 June 2020, pre-tax losses widened to £2.9m from £2.4m on-year.
Administrative costs increased to £2.9m from £2.6m.
Looking ahead, the company said it was well funded to complete the Phase 2 clinical development of its lead drug asset, XF-73.
'The company is currently designing the phase 3 clinical study that will hopefully follow,' it added.
At 8:02am: (LON:DEST) Destiny Pharma Plc share price was 0p at 58p